Home
Search
Study Topics
Glossary
|
|
|
|
|
Sponsored by: |
Pfizer |
---|---|
Information provided by: | Pfizer |
ClinicalTrials.gov Identifier: | NCT00645424 |
The purpose of this study is to evaluate the efficacy and safety of atorvastatin for the treatment of Taiwanese patients with diabetes and high cholesterol.
Condition | Intervention | Phase |
---|---|---|
Hyperlipidemias |
Drug: atorvastatin |
Phase IV |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Open Label, Parallel Assignment, Safety/Efficacy Study |
Official Title: | A Randomized, 12-Week, Open Labeled Study To Evaluate The Efficacy And Safety Of Once Daily Atorvastatin In Diabetes Mellitus Type 2 With Hyperlipidemia |
Enrollment: | 155 |
Study Start Date: | December 2003 |
Study Completion Date: | October 2004 |
Arms | Assigned Interventions |
---|---|
Arm A: Experimental |
Drug: atorvastatin
Atorvastatin calcium tablets 10 mg orally once daily in the evening for 12 weeks
|
Arm B: Experimental |
Drug: atorvastatin
Atorvastatin calcium tablets 20 mg orally once daily in the evening for 12 weeks
|
Arm C: Experimental |
Drug: atorvastatin
Atorvastatin calcium tablets 40 mg orally once daily in the evening for 12 weeks
|
Ages Eligible for Study: | 18 Years to 80 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Taiwan | |
Pfizer Investigational Site | |
Taichung, Taiwan | |
Pfizer Investigational Site | |
Kaohsiung Hsien, Taiwan | |
Pfizer Investigational Site | |
Kaohsiung, Taiwan | |
Pfizer Investigational Site | |
Taoyuan Hsien, Taiwan | |
Pfizer Investigational Site | |
Taipei, Taiwan |
Study Director: | Pfizer CT.gov Call Center | Pfizer |
Responsible Party: | Pfizer, Inc. ( Director, Clinical Trial Disclosure Group ) |
Study ID Numbers: | A2581123 |
Study First Received: | March 24, 2008 |
Last Updated: | April 28, 2008 |
ClinicalTrials.gov Identifier: | NCT00645424 History of Changes |
Health Authority: | Taiwan: Department of Health |
Antimetabolites Hyperlipidemias Metabolic Diseases Antilipemic Agents Diabetes Mellitus Anticholesteremic Agents Hydroxymethylglutaryl-CoA Reductase Inhibitors |
Calcium, Dietary Diabetes Mellitus, Type 2 Metabolic Disorder Dyslipidemias Atorvastatin Lipid Metabolism Disorders |
Antimetabolites Hyperlipidemias Metabolic Diseases Molecular Mechanisms of Pharmacological Action Antilipemic Agents Enzyme Inhibitors Anticholesteremic Agents |
Hydroxymethylglutaryl-CoA Reductase Inhibitors Pharmacologic Actions Therapeutic Uses Dyslipidemias Atorvastatin Lipid Metabolism Disorders |